🇺🇸 FDA
Pipeline program

Odronextamab

RG1124641

Phase 2 mab active

Quick answer

Odronextamab for Recurrent Diffuse Large B-Cell Lymphoma is a Phase 2 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Recurrent Diffuse Large B-Cell Lymphoma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials